Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 4, 2014, Pages 773-783

  Hodges, Joseph C ^a   Beg, Muhammad S ^a   Das, Prajnan ^b   Meyer, Jeffrey ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; COST EFFECTIVENESS; DIAGNOSIS; DISEASES; PHYSICAL THERAPY; RADIOTHERAPY; SENSITIVITY ANALYSIS; TOXICITY;

CONCURRENT CHEMOTHERAPY; CONFORMAL RADIATION THERAPY; COST EFFECTIVENESS ANALYSIS; COST-EFFECTIVENESS RATIOS; INTENSITY-MODULATED RADIATION THERAPY; MARKOV DECISION MODEL; METHODS AND MATERIALS; PROBABILISTIC SENSITIVITY ANALYSIS;

COST BENEFIT ANALYSIS;

CISPLATIN; FLUOROURACIL; MITOMYCIN;

ACUTE TOXICITY; ADJUVANT CHEMORADIOTHERAPY; AGED; ANUS CANCER; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; COLOSTOMY; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEALTH STATUS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIATION INJURY; REPRODUCTIVE TOXICITY; SALVAGE THERAPY; SENSITIVITY ANALYSIS; SEXUAL DYSFUNCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

AGED; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COLOSTOMY; COST-BENEFIT ANALYSIS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; SENSITIVITY AND SPECIFICITY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT FAILURE;

EID: 84903276844     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.02.012     Document Type: Article

References (35)

1. L.A. Kachnic, H.K. Tsai, and J.J. Coen et al. Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy Int J Radiat Oncol Biol Phys 82 2012 153 158
2. L.L. Gunderson, K.A. Winter, and J.A. Ajani et al. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin J Clin Oncol 30 2012 4344 4351
3. L. Kachnic Early efficacy results of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluououracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal Int J Radiat Oncol Biol Phys 78 2010 S55
4. M.C. Weinstein, and J.A. Skinner Comparative effectiveness and health care spending - implications for reform N Engl J Med 362 2010 460 465
5. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: A practical guide Med Decis Making 13 1993 322 338
6. M.P. Mitchell, M. Abboud, and C. Eng et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: Outcomes and toxicity Am J Clin Oncol 2013 Mar 4 10.1097/COC.0b013e31827e52a3 [Epub ahead of print]
7. L.A. Kachnic, K. Winter, and R.J. Myerson et al. RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal Int J Radiat Oncol Biol Phys 86 2013 27 33
8. E. Ben-Josef, J. Moughan, and J.A. Ajani et al. Impact of overall treatment time on survival and local control in patients with anal cancer: A pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11 J Clin Oncol 28 2010 5061 5066
9. M. John, T. Pajak, and M. Flam et al. Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08 Cancer J Sci Am 2 1996 205 211
10. A.S. Allal, M.A. Sprangers, and F. Laurencet et al. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy Br J Cancer 80 1999 1588 1594
11. C.R. Jephcott, C. Paltiel, and J. Hay Quality of life after non-surgical treatment of anal carcinoma: A case control study of long-term survivors Clin Oncol (R Coll Radiol) 16 2004 530 535
12. L. Tournier-Rangeard, M. Mercier, and D. Peiffert et al. Radiochemotherapy of locally advanced anal canal carcinoma: Prospective assessment of early impact on the quality of life (randomized trial ACCORD 03) Radiother Oncol 87 2008 391 397
13. S. Provencher, C. Oehler, and S. Lavertu et al. Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma Radiat Oncol 5 2010 41
14. M.M. Versteegh, A. Leunis, and J.J. Luime et al. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D Med Decis Making 32 2012 554 568
15. L.K. Temple, D. Naimark, and R.S. McLeod Decision analysis as an aid to determining the management of early low rectal cancer for the individual patient J Clin Oncol 17 1999 312 318
16. R.S. McLeod, D.N. Churchill, and A.M. Lock et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively Gastroenterology 101 1991 1307 1313
17. N.L. Liberato, C. Rognoni, and S. Rubrichi et al. Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: A cost-utility analysis Ann Oncol 23 2012 1825 1832
18. S. Varadarajulu, A. Roy, and T. Lopes et al. Endoscopic stenting versus surgical colostomy for the management of malignant colonic obstruction: Comparison of hospital costs and clinical outcomes Surg Endosc 25 2011 2203 2209
19. S. Meisner, P.A. Lehur, and B. Moran et al. Peristomal skin complications are common, expensive, and difficult to manage: A population based cost modeling study PloS One 7 2012 e37813
20. M.C. Weinstein, B. O'Brien, and J. Hornberger et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies Value Health 6 2003 9 17
21. W.C. Winkelmayer, M.C. Weinstein, and M.A. Mittleman et al. Health economic evaluations: The special case of end-stage renal disease treatment Med Decis Making 22 2002 417 430
22. N. Devlin, and D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 2004 437 452
23. C. Donaldson, R. Baker, and H. Mason et al. The social value of a QALY: Raising the bar or barring the raise? BMC Health Serv Res 11 2011 8
24. P. Das, S.B. Cantor, and C.L. Parker et al. Long-term quality of life after radiotherapy for the treatment of anal cancer Cancer 116 2010 822 829
25. R. Rabin, and F. de Charro EQ-5D: A measure of health status from the EuroQol Group Ann Med 33 2001 337 343
26. A.S. Allal, F.M. Laurence, M.A. Reymond, J.M. Kurtz, and M.C. Marti Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment Cancer 86 1999 405 409
27. J.T. Mullen, M.A. Rodriguez-Bigas, and G.J. Chang et al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal Ann Surg Oncol 14 2007 478 483
28. C. Faivre, P. Rougier, and M. Ducreux et al. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer] Bull Cancer 86 1999 861 865
29. J.A. Ajani, K.A. Winter, and L.L. Gunderson et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial JAMA 299 2008 1914 1921
30. A. Lloyd, P. van Hanswijck de Jonge, S. Doyle, and P. Cornes Health state utility scores for cancer-related anemia through societal and patient valuations Value Health 11 2008 1178 1185
31. Vaginismus.com. 2013; Available from: http://www.vaginismus.com/products/ dilator-set.
32. S.B. Cantor, D.V. Hudson Jr., B. Lichtiger, and E.B. Rubenstein Costs of blood transfusion: A process-flow analysis J Clin Oncol 16 1998 2364 2370
33. P.Y. Cremieux, B. Barrett, K. Anderson, and M.B. Slavin Cost of outpatient blood transfusion in cancer patients J Clin Oncol 18 2000 2755 2761
34. L.C. Jefferies, B.S. Sachais, and D.S. Young Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995 Transfusion 41 2001 522 529
35. M.B. Schilling, C. Parks, and R.G. Deeter Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study Exp Ther Med 2 2011 859 866